77 related articles for article (PubMed ID: 17439836)
21. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
[TBL] [Abstract][Full Text] [Related]
22. CD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphoma.
Ait-Tahar K; Barnardo MC; Pulford K
Cancer Res; 2007 Mar; 67(5):1898-901. PubMed ID: 17332315
[TBL] [Abstract][Full Text] [Related]
23. Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma.
Lai R; Medeiros LJ; Dabbagh L; Formenti KS; Coupland RW
Mod Pathol; 2000 Mar; 13(3):223-8. PubMed ID: 10757332
[TBL] [Abstract][Full Text] [Related]
24. [Expression of anaplastic lymphoma kinase and survivin proteins in anaplastic large cell lymphoma and its significance].
Li JF; Li GD; Liu WP; Wang Y; Cheng JR; Chen Y; Yang H; Tang HL; Bai YQ; Lin DG; DU LH; Peng FX; Yang YH; Zhao C
Zhonghua Bing Li Xue Za Zhi; 2006 Apr; 35(4):213-7. PubMed ID: 16776978
[TBL] [Abstract][Full Text] [Related]
25. Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: a report from CCG-E08.
Lones MA; Heerema NA; Le Beau MM; Perkins SL; Kadin ME; Kjeldsberg CR; Sposto R; Meadows A; Siegel S; Buckley J; Finlay J; Abromowitch M; Cairo MS; Sanger WG
Cancer Genet Cytogenet; 2006 Dec; 171(2):89-96. PubMed ID: 17116485
[TBL] [Abstract][Full Text] [Related]
26. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
Yamamoto R; Nishikori M; Tashima M; Sakai T; Ichinohe T; Takaori-Kondo A; Ohmori K; Uchiyama T
Cancer Sci; 2009 Nov; 100(11):2093-100. PubMed ID: 19703193
[TBL] [Abstract][Full Text] [Related]
27. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type.
Pileri SA; Pulford K; Mori S; Mason DY; Sabattini E; Roncador G; Piccioli M; Ceccarelli C; Piccaluga PP; Santini D; Leone O; Stein H; Falini B
Am J Pathol; 1997 Apr; 150(4):1207-11. PubMed ID: 9094977
[TBL] [Abstract][Full Text] [Related]
28. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL).
Mencía-Gutiérrez E; Gutiérrez-Díaz E; Salamanca J; Martínez-González MA
Int J Dermatol; 2006 Jun; 45(6):766-9. PubMed ID: 16796648
[TBL] [Abstract][Full Text] [Related]
30. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
31. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
32. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol.
Rosolen A; Pillon M; Garaventa A; Burnelli R; d'Amore ES; Giuliano M; Comis M; Cesaro S; Tettoni K; Moleti ML; Tamaro P; Visintin G; Zanesco L
Cancer; 2005 Nov; 104(10):2133-40. PubMed ID: 16211546
[TBL] [Abstract][Full Text] [Related]
33. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation.
Sasaki K; Sugaya M; Fujita H; Takeuchi K; Torii H; Asahina A; Tamaki K
Br J Dermatol; 2004 Jun; 150(6):1202-7. PubMed ID: 15214912
[TBL] [Abstract][Full Text] [Related]
34. Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases.
Kesler MV; Paranjape GS; Asplund SL; McKenna RW; Jamal S; Kroft SH
Am J Clin Pathol; 2007 Aug; 128(2):314-22. PubMed ID: 17638668
[TBL] [Abstract][Full Text] [Related]
35. Pediatric inflammatory myofibroblastic tumor: anaplastic lymphoma kinase (ALK) expression and prognosis.
Chun YS; Wang L; Nascimento AG; Moir CR; Rodeberg DA
Pediatr Blood Cancer; 2005 Nov; 45(6):796-801. PubMed ID: 15602716
[TBL] [Abstract][Full Text] [Related]
36. Cytologic and immunocytochemical findings of anaplastic large cell lymphoma: analysis of ten fine-needle aspiration specimens over a 9-year period.
Ng WK; Ip P; Choy C; Collins RJ
Cancer; 2003 Feb; 99(1):33-43. PubMed ID: 12589644
[TBL] [Abstract][Full Text] [Related]
37. ALK+ anaplastic large cell lymphoma exhibits phosphatidylinositol-3 kinase/Akt activity with retained but inactivated PTEN--a report from the Children's Oncology Group.
Thakral C; Hutchison RE; Shrimpton A; Barrett D; Laver J; Link M; Halleran DR; Hudson S
Pediatr Blood Cancer; 2012 Sep; 59(3):440-7. PubMed ID: 22488797
[TBL] [Abstract][Full Text] [Related]
38. Association of expression of CD44v6 with systemic anaplastic large cell lymphoma: comparison with primary cutaneous anaplastic large cell lymphoma.
Liang X; Golitz LE; Smoller BR; Meech SJ; Odom LF; Williams SA; Ryder JW
Am J Clin Pathol; 2002 Feb; 117(2):276-82. PubMed ID: 11863224
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ; Choi YL; Sung KW; Kang SY; Park SM; Choi SY; Kim JS; Suh YL
Pathol Res Pract; 2011 Oct; 207(10):634-9. PubMed ID: 21940108
[TBL] [Abstract][Full Text] [Related]
40. Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL.
Mussolin L; Bonvini P; Ait-Tahar K; Pillon M; Tridello G; Buffardi S; Lombardi A; Pulford K; Rosolen A
Leukemia; 2009 Feb; 23(2):400-2. PubMed ID: 18615104
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
